Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 10 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
Georgetown University has 11 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 11 examiners and 10 art units, indicating broad examiner distribution across a slightly smaller set of technical units.
BAUER, NICOLA MARIA is the busiest examiner, with 1 pending matter. The examiner-level distribution is therefore dispersed rather than concentrated with one individual. Counsel should maintain matter-specific tracking across the docket and identify any recurring practice within the shared art-unit structure.
The relationship between the pending-action count and examiner count indicates a broad set of assignments, while the art-unit count shows that at least some technical units include more than one examiner. A coordinated portfolio process should combine examiner monitoring with art-unit-level review.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (18%) |
| §103 only | 1 (9%) |
| §102 only | 1 (9%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 5 (45%) |
| No statute on record | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, NICOLA MARIA | 1 | 58.7% | +52.1% |
| GABEL, GAILENE | 1 | 75.6% | +44.7% |
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
| PETERS, ALEC JON | 1 | 67.4% | +54.8% |
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| JUEDES, AMY E | 1 | 44.7% | +41.9% |
| TRAN, KHOA NHAT | 1 | 41.9% | +50.5% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17387090 | GENERATING HYPOTHESES IN DATA SETS | RIFKIN, BEN M | 10d overdue |
| 18859396 | USE OF LAT1 INHIBITORS TO TREAT OBESITY | BAUER, NICOLA MARIA | — |
| 18584188 | ASSAYS AND METHODS OF USE OF THOSE ASSAYS IN THE CARE AND DIAGNOSIS OF STROKE PATIENTS | GABEL, GAILENE | — |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | GOLDBERG, JEANINE ANNE | — |
| 18263129 | FIBROBLAST ACTIVATION PROTEIN MODULATION TO ALTER IMMUNE CELL MIGRATION AND TUMOR INFILTRATION | PETERS, ALEC JON | — |
| 18042405 | STEM CELL-LIKE MEMORY T CELLS AND USES THEREOF | JUEDES, AMY E | — |
| 17921606 | METHODS FOR ISOLATING AND CULTURING TUMOR CELLS | TRAN, KHOA NHAT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18138058 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION | BARSKY, JARED | 89d overdue |
| 17659274 | TREATING NEURAL DISEASE WITH TYROSINE KINASE INHIBITORS | COPPINS, JANET L | 51d overdue |
| 18859396 | USE OF LAT1 INHIBITORS TO TREAT OBESITY | BAUER, NICOLA MARIA | — |
| 18584188 | ASSAYS AND METHODS OF USE OF THOSE ASSAYS IN THE CARE AND DIAGNOSIS OF STROKE PATIENTS | GABEL, GAILENE | — |
| 18436808 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES | STOICA, ELLY GERALD | — |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | GOLDBERG, JEANINE ANNE | — |
| 18263129 | FIBROBLAST ACTIVATION PROTEIN MODULATION TO ALTER IMMUNE CELL MIGRATION AND TUMOR INFILTRATION | PETERS, ALEC JON | — |
| 18260721 | USP13 INHIBITORS AND METHODS OF USE THEREOF | CHONG, YONG SOO | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1621 | 1 |
| 1678 | 1 |
| 1647 | 1 |
| 1682 | 1 |
| 1641 | 1 |
| 1623 | 1 |
| 1644 | 1 |
| 1632 | 1 |
| 2123 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18859396 | USE OF LAT1 INHIBITORS TO TREAT OBESITY | BAUER, NICOLA MARIA | 1621 | §102§103 | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18584188 | ASSAYS AND METHODS OF USE OF THOSE ASSAYS IN THE CARE AND DIAGNOSIS OF STROKE PATIENTS | GABEL, GAILENE | 1678 | §103§112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18436808 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES | STOICA, ELLY GERALD | 1647 | §112DP | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | GOLDBERG, JEANINE ANNE | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18263129 | FIBROBLAST ACTIVATION PROTEIN MODULATION TO ALTER IMMUNE CELL MIGRATION AND TUMOR INFILTRATION | PETERS, ALEC JON | 1641 | §103§112 | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18260721 | USP13 INHIBITORS AND METHODS OF USE THEREOF | CHONG, YONG SOO | 1623 | §102 | Non-Final OA | — | Pending | Jul 07, 2023 |
| 18138058 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION | BARSKY, JARED | 1628 | §103 | Final Rejection | 89d overdue | Pending | Apr 22, 2023 |
| 18042405 | STEM CELL-LIKE MEMORY T CELLS AND USES THEREOF | JUEDES, AMY E | 1644 | §102§103§112 | Final Rejection | — | Pending | Feb 21, 2023 |
| 17921606 | METHODS FOR ISOLATING AND CULTURING TUMOR CELLS | TRAN, KHOA NHAT | 1632 | §103§112 | Non-Final OA | — | Pending | Oct 26, 2022 |
| 17659274 | TREATING NEURAL DISEASE WITH TYROSINE KINASE INHIBITORS | COPPINS, JANET L | 1628 | — | Final Rejection | 51d overdue | Pending | Apr 14, 2022 |
| 17387090 | GENERATING HYPOTHESES IN DATA SETS | RIFKIN, BEN M | 2123 | §101§112Other | Final Rejection | 10d overdue | Pending | Jul 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGeorgetown University has 11 pending office actions as of October 2026, spread across 10 art units and 11 examiners.
Nicola Maria Bauer has the most, with 1 of Georgetown University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
